Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles

Kyoung Mee Kim1,2
Hyun Kyung Lim1,2
Sang Hee Shim1,2
Joohee Jung1,2

1College of Pharmacy, 2Innovative Drug Center, Duksun Women’s University, Seoul, Republic of Korea

Abstract: Chrysin is a flavone that is found in several plants and in honeycomb and possesses various biological activities. However, its low solubility means it has poor bioavailability, which must be resolved to enable its pharmaceutical applications. In the present study, chrysin was incorporated into methoxy poly(ethylene glycol)-β-polycaprolactone nanoparticles (chrysin-NPs) using the oil-in-water technique in order to overcome problems associated with chrysin. The properties of chrysin-NPs were analyzed, and their anticancer effects were investigated in vitro and in vivo. Chrysin-NPs were 77 nm sized (as determined by dynamic laser light scattering) and showed a monodisperse distribution. The zeta potential of chrysin-NPs was ~2.22 mV, and they were spherically shaped by cryo-transmission electron microscopy (cryo-TEM). The loading efficiency of chrysin-NPs was 46.96%. Chrysin-NPs retained the cytotoxicity of chrysin in A549 cells. The therapeutic efficacies of chrysin-NPs were compared with those of chrysin in an A549-derived xenograft mouse model. Chrysin-NPs were intravenously injected at a 10 times lower dosage than chrysin 3 times per week (q2d). However, free chrysin was orally administrated 5 times per week (q1d). Chrysin-NP-treated group showed significant tumor growth delay, which was similar to that of chrysin-treated group, despite the considerably lower total dosage. These results suggest that the injectable chrysin-NPs enhance therapeutic efficacy in vivo and offer a beneficial formulation for chemotherapy.

Keywords: chrysin, nanoparticle, chemotherapeutic efficacy, non-small-cell lung cancer, in vivo model

Introduction

Lung cancer is the leading cause of cancer-related death in Korea and is among the leading causes of cancer-related death worldwide.1 In particular, non-small-cell lung cancer constitutes 85% of lung cancer cases and tends to develop resistance to chemotherapy. Thus, novel chemotherapeutic agents are needed to treat non-small-cell lung cancer.

Chrysin is a natural active component found in various herbs, mushroom, and propolis2 and has anti-inflammatory,3,4 antiaging,5 antiviral,6 antioxidant,7–9 antidiabetes,10 antiaromatase,11,12 and anticancer13–16 activities. Accordingly, it is widely held that chrysin has potential pharmaceutical applications. A combination of chrysin and cisplatin was reported to enhance anticancer effects in human malignant glioma cells,17 HepG2 cells,18 and drug-resistant cells.19 In a previous study, we reported that chrysin enhanced chemotherapeutic efficacy of docetaxel in a non-small-cell lung cancer model.20 However, the low solubility of chrysin means that its bioavailability is poor, and its half-life is only 13 min in human hepatocytes.21 Thus, these obstacles must be resolved before it can be used pharmaceutically. Currently, many researchers consider chrysin a drug sensitizer in integrative therapies because chrysin alone has low...
chemotherapeutic efficacy. However, chemical modification of chrysin has become the focus of research attention in order to resolve the abovementioned problem.\textsuperscript{21} An oxido-vanadium complex with chrysin was reported to improve chemotherapy in a colon adenocarcinoma model\textsuperscript{22} and in an osteosarcoma model.\textsuperscript{23} Furthermore, methoxy poly(ethylene glycol) (mPEG)–chrysin conjugates were reported to increase the encapsulation efficacy of doxorubicin and to enhance its anticancer effects.\textsuperscript{24} Poly(\(d\),\(l\)-lactic-co-glycolic acid)-PEG (PLGA-PEG) has also been utilized to produce nanoparticles (NPs), including chrysin.\textsuperscript{25,26} To date, chrysin formulations have mainly been investigated in vitro. Thus, evaluations of chrysin formulations and knowledge of the anticancer mechanism of chrysin in vivo are needed to aid drug development.

In this study, we formulated injectable chrysin-including NPs (chrysin-NPs) and evaluated them in non-small-cell lung cancer cells (A549 cells) and in an A549-xenograft model with a view toward their pharmaceutical applications.

**Materials and methods**

**Preparation of chrysin-NPs**

Chrysin (Sigma-Aldrich, St Louis, MO, USA) was incorporated into copolymer NPs using an oil-in-water technique (Figure 1). mPEG–\(\beta\)-polycaprolactone copolymer (mPEG-PCL, 50 mg; 2,000:5,200 Da; PolysciTech, West Lafayette, IN, USA) and 5 mg of chrysin were dissolved in a dichloromethane (Duksan reagent, Gyeonggi-do, Korea) and methanol mixture (Duksan reagent; v/v, 1.5:1). This solution (2.5 mL) was added to a 1% aqueous polyvinyl alcohol solution (6 mL) and was emulsified by sonification for 1 min. The solvent was removed by evaporation under stirring to produce NPs. To remove polyvinyl alcohol and surplus free chrysin, the supernatant was collected after centrifugation (14,000 rpm) twice at room temperature for 1 h.

**Characterization of chrysin-NPs**

Size distributions and zeta potentials of chrysin-NPs were determined by dynamic light scattering (DLS) using a Zetasizer Nano-ZS device (Malvern Instruments Ltd., Worcestershire, UK). Polydispersity index (PDI) represents a width parameter for the size-average as an intensity mean. Chrysin-NP morphology was observed by cryo-TEM (Cryo Tecnai F20; FEI Co., Hillsboro, OR, USA). Chrysin-loading efficiencies were calculated using Equation 1. Free nonencapsulated chrysin was dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and quantified by high-performance liquid chromatography (Agilent Technologies, Inc., Santa Clara, CA, USA) and confirmed at 348 nm using a microplate reader (Infinite M200 PRO; Tecan Inc., Grödig, Austria).

\[
\text{Equation 1}
\]

\[
\% \text{ Loading efficiency} = \left( \frac{\text{Chrysin-NP concentration}}{\text{Chrysin-NP concentration + free chrysin concentration}} \right) \times 100
\]
Chrysin-loading efficiency (%) = \[
1 - \frac{\text{Free chrysin}}{\text{Total used amount of chrysin}} \times 100
\] (1)

In vitro release of chrysin from NPs
Amounts of chrysin released by chrysin-NPs were determined after 0, 1, 4, 8, 12, 24, or 48 h with stirring at 37°C in phosphate-buffered saline (PBS, pH 7.4, 0.1 M) by measuring absorbance at 348 nm using a microplate reader.

Cell culture
A549 cells (ATCC no CCL-185) were maintained in F-12K medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (GenDEPOT, Barker, TX, USA) and 1% penicillin/streptomycin (GenDEPOT) in a humidified 5% CO₂ atmosphere at 37°C.

MTT assay
A549 cells (2,000 cells/well) were seeded in 96-well plates and incubated for 24 h, and chrysin or chrysin-NPs were added for 48 h. MTT (Sigma-Aldrich) was then added to media for 4 h, and media were discarded. DMSO (Sigma-Aldrich) was then added and absorbance (560 nm) was determined using a microplate reader (Infinite M200 PRO). The data represented average ± standard deviation (SD; n=8).

In vivo tumor growth delay
All animal experiments were performed according to a protocol approved beforehand by the institutional animal care and use committee of Duksung Women’s University (No. 2015-017-005) in accordance with the guidelines of the care and use of laboratory animals, Duksung Women’s University, Korea. A549 cells (5x10⁶ cells/mice) were implanted subcutaneously into mice. The mice bearing an A549-derived tumor 100–150 mm³ in size were randomly divided to 3 groups (n=5/group). Chrysin (50 mg/kg) was orally (p.o.) administrated once a day, 5 times per week for 3 weeks, and chrysin-NPs (5 mg/kg) were intravenously injected every 2 days, 3 times per week for 3 weeks. Tumor sizes and mouse body weights were measured. Tumor volumes were calculated using the following equation.

\[
\text{Tumor volume (mm}^3\text{)} = (\text{Length} \times \text{Width}^2) \times 0.5
\] (2)

The results are presented as mean ± SD values.

Tissue preparation for histological analysis
After measuring final tumor sizes, tumor tissues were isolated from sacrificed mice and molded into optimal cutting temperature (OCT) compound (Leica, Nussloch, Germany). Frozen blocks were sliced to produce 5 μm thick sections using a cryotome (Leica).

TUNEL assay
Sections were hydrated with 70% ethanol, bathed in 3% H₂O₂/distilled water (DW), washed with DW twice, incubated in DW at 60°C for 1 h, cooled to room temperature, treated with terminal deoxynucleotidyl transferase (TdT) labeling buffer, and then incubated in TdT (Sigma)/biotinylated deoxyuridine (Roche Diagnostics, Mannheim, Germany) diluted in TdT labeling buffer for 1 h at 37°C in a humid chamber. The reaction was stopped using terminating buffer, and slides were washed with DW. The tissue sections were then blocked with 2% bovine serum albumin (BSA; bioWORLD, Dublin, OH, USA) in PBS, washed in PBS, incubated with ABC complex, washed with 0.05 M Tris buffer, colorized with DAB (Vector laboratories, Inc., Burlingame, CA, USA), and examined under a Nikon eclipse microscope (Nikon Instruments Inc., Melville, NY, USA).

Immunofluorescence staining
Sections were washed with 1% BSA in PBS containing Tween80 (0.1% v/v) twice, incubated with anti-Ki-67 antibody (1:100) overnight at 4°C, washed 3 times, incubated with Cy7-conjugated antimouse antibody (1:300) for 2 h, and stained with 4’,6-diamidino-2-phenylindol (DAPI) solution. Ki-67 staining was analyzed under a fluorescence microscope (DMi8, ×20, Leica).

Western blot analysis
Isolated tumor tissues were homogenized with radioimmuno-precipitation assay (RIPA) buffer (GenDEPOT) containing protease inhibitor and phosphatase inhibitor (GenDEPOT), and extracted proteins were quantified using a bicinchoninic acid (BCA) assay (Thermo Scientific, Waltham, MA, USA). Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Darmstadt, Germany). Membranes were blocked with 5% skimmed milk in tris-buffered saline with polysorbate 20 (TBST) (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween20), incubated with p53 antibody (1:1,000), p21 antibody (1:1,000), or β-actin antibody (1:5,000) at 4°C, overnight, and then with secondary antibody (1:3,000) at room temperature for 3 h. Blots were visualized using enhanced chemiluminescent (ECL) solution and observed by ChemiDoc (FluorChemE, Germany).
Results

Characterization of chrysin-NPs

Chrysin-NPs produced using the scheme shown in Figure 1A were yellowish in color in aqueous solution (Figure 1B). The polymer emulsion was white, but the inclusion of chrysin-NPs produced a yellow tint. The size distribution of chrysin-NPs indicated monodispersed particle as shown in Figure 2A. The average diameter of chrysin-NPs was 66.86 nm (PDI, 0.148) as determined by DLS (Table 1), and their zeta-potential was $-2.22 \text{ mV}$ (Figure 2B and Table 1).

As shown in Figure 2C, chrysin-NPs were spherical and particle size observed by cryo-TEM agreed with DLS-determined sizes. Chrysin-NPs exhibited a $46.96\% \pm 1.12\%$ encapsulation efficiency and $2.3 \text{ mg}$ of chrysin was incorporated into $50 \text{ mg}$ of NPs (4.6%, loading percentage; Table 1).

Additionally, the stability of chrysin-NPs remained at $4^\circ \text{C}$ rather than $37^\circ \text{C}$ (Figure S1).

In vitro release of chrysin from chrysin-NPs

Chrysin-NPs in PBS time-dependently released chrysin. During the early phase (the first hour), chrysin was rapidly released, but it was released slowly in the late phase. Passive release of chrysin in PBS without solubilizer for 48 h at $37^\circ \text{C}$ was 50% (Figure 3).

Cytotoxicity of chrysin-NPs

Chrysin was previously reported to reduce cell viability in vitro. Thus, we investigated whether chrysin-NPs were as cytotoxic as free chrysin using A549 cells. As shown

Table I Characterization of chrysin-NPs

<table>
<thead>
<tr>
<th></th>
<th>Size (PDI)$^a$</th>
<th>Zeta potential (SD)$^a$</th>
<th>Encapsulated efficiency</th>
<th>Loading content/polymer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chrysin-NPs</td>
<td>77.15 nm (0.148)</td>
<td>$-2.22 \text{ mV}$ (4.9)</td>
<td>$46.96% \pm 1.12%$</td>
<td>$2.3 \pm 0.05 \text{ mg/50 mg}$</td>
</tr>
</tbody>
</table>

Note: $^a$Data were determined by dynamic light scattering.

Abbreviations: NPs, nanoparticles; PDI, polydispersity index; SD, standard deviation.
in Figure 4, chrysin-NPs dose-dependently reduced cell viability. IC<sub>50</sub> values of chrysin and chrysin-NPs were 6.89 μM and 2.5 M, respectively. The cytotoxicity of chrysin-NPs was not as great as that of chrysin, suggesting that chrysin from NPs was more slowly taken up by cells. In addition, the cytotoxicity of chrysin-NPs was due to chrysin, not NPs. Nonloaded NPs were found to have no cytotoxic effect by clonogenic assay (Figure S2).

Tumor growth delay by chrysin-NPs
We investigated whether chrysin-NPs could improve therapeutic efficacy of chrysin using an A549-derived xenograft model. Chrysin (50 mg/kg) was p.o. administrated once a day, 5 times per week because of its insoluble nature. On the other hand, chrysin-NPs were intravenously injected every 2 days, 3 times per week at 5 mg/kg. Despite the dosage difference, chrysin-NPs delayed tumor growth to the same extent as chrysin (Figure 5A), and tumor weights in the chrysin-NP- and chrysin-treated groups reduced compared with the control group (Figure 5B). However, intergroup differences were not significantly shown because intragroup variation was large in the control group.

Inhibited proliferation and apoptosis induction by chrysin-NPs
For elucidating the therapeutic mechanism of chrysin-NPs, we observed Ki-67 expression as a marker of proliferation in tumor tissues. As shown in Figure 6A, cells stained with DAPI were not different among each group, but Ki-67 expression was lower in the chrysin and chrysin-NP groups than in the control group. Chrysin-NPs were found to inhibit the proliferation of A549-derived tumors, and apoptosis induction was greater in the chrysin-NP group than in the control or chrysin groups (Figure 6B). Apoptotic cells appeared brown as indicated by black arrows. These results indicated that chrysin-NPs reduced cellular proliferation and increased apoptotic cell death. To investigate the underlying molecular mechanism, we assessed p53 and p21 levels by Western blotting (Figure 6C). P53 plays a key role in apoptosis, and p21 is a target protein of p53 and a cell cycle control factor. Thus, we investigated whether changing p53 or p21 levels inhibited proliferation or induced apoptosis in vivo. Chrysin-NPs were found to induce p53 and p21 levels versus controls. These results suggest that chrysin-NPs suppressed cell proliferation and induced apoptosis via the p53-p21 pathway.

Discussion
In this study, we demonstrate that mPEG-PCL in NP form can encapsulate chrysin, improve its bioavailability, and thus, its chemotherapeutic efficacy. In particular, the chrysin-NPs produced were injectable and reduced dosage and treatment times compared with oral chrysin, as determined using a non-small-cell lung cancer A549 cell-derived xenograft model.

mPEG-PCL is biodegradable and biocompatible and is thus suitable for use in the pharmaceutical field. Moreover, insoluble drugs (eg, curcumin, rapamycin) can be encapsulated in mPEG-PCL. In the present study, chrysin-NPs produced using mPEG-PCL were found to be nanosized (66.86 nm).
in water and to form micelles (Figure 2). The stability of chrysin-NP at 4°C was better than that at 37°C. Thus, we stored chrysin-NPs at 4°C and used them within 12 h of preparation for experiments. Lyophilization of chrysin-NPs was not considered in this study, but it might provide a better means of long-term storage. The use of pegylated PCL is expected to prevent NPs from being engulfed by phagocytes and thus increase the in vivo half-life of chrysin. In addition, chrysin-NPs slowly released chrysin in PBS (pH 7.4) after 1 h (Figure 3). These results indicate that administration frequency of chrysin-NP was decreased without reduced efficacy (Figure 5).

In terms of cytotoxicity, chrysin-NPs were not as potent as free chrysin (Figure 4), indicating that chrysin-NPs might not release chrysin for cell uptake for 48 h. However, chrysin-NPs dose-dependently inhibited cell viability, suggesting that chrysin-NPs maintained the activity of chrysin. In our in vivo assay, chrysin-NPs showed significant tumor growth delay. The results showed that chrysin-NPs reduced 20 times dosage than chrysin because of injectable chrysin-NPs (Figure 5).

Suspension formulations enable delivery by intravenous (iv) injection, whereas oral administration involves absorption in the gastrointestinal track, which invariably reduces drug concentrations in blood. In pharmacokinetic studies, iv injection of chrysin resulted in higher concentrations in blood than p.o. treated chrysin. In a previous study, NPs were found to allow dosage reduction as was found in the present study. Furthermore, chrysin-NPs probably accumulate in tumor tissues due to their enhanced permeability and retention (EPR) effect.

The anticancer effects of chrysin have been reported in various cancer cell lines. In the present study, chrysin-NPs were observed to have anticancer effects in A549-derived tumor tissues. In fact, chrysin-NPs inhibited cell proliferation and induced apoptosis in tumor tissues (Figure 6). In our previous study, we reported that chrysin induced the apoptosis-related factors p53, p21, and cytochrome C in A549 cells. Thus, we investigated the effects of chrysin-NPs on p53 and p21 protein levels in A549-derived tumor tissues. As was expected, chrysin-NPs increased the levels of p53 and

Figure 5 Suppression of tumor growth by chrysin-NPs in vivo.

Notes: Balb/c nude mice bearing an A549-derived tumor were treated with chrysin-NPs (i.v., 3 times per week) or chrysin (p.o., 5 times per week) for 3 weeks. (A) Tumor growth curve. Data shows mean ± SD (n=5). (B) Photograph of isolated tumor tissues after final tumor growth measurements. (C) Tumor weights. Data shows mean ± SD (n=5).

Abbreviations: NPs, nanoparticles; i.v., intravenously; p.o., orally; SD, standard deviation; w, week.
Figure 6 Anticancer effects of chrysin-NPs in A549-derived tumor tissues.

Notes: (A) Suppression of proliferation by chrysin-NPs. Ki-67 was used as a marker of proliferation (red). Scale bar =50 μm. (B) Chrysin-NP induced apoptosis as observed by TUNEL assay. Brown spots represent apoptotic cells (black arrows). (C) Inductions of p53 and p21 proteins by chrysin-NPs.

Abbreviation: NPs, nanoparticles.
p21 (Figure 6C). These results showed that chrysin-NPs, like chrysin, induced apoptosis via the p53-p21 pathway in vivo.

**Conclusion**

Chrysin-NPs were found to enable administration of chrysin by injection and to improve the bioavailability and therapeutic efficacy of chrysin in an A549-xenograft model. Our in vitro and in vivo results suggest that chrysin-NPs have potential use as a chemotherapeutic agent.

**Acknowledgments**

This research was supported by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2016R1A6A1A03007648), a grant from the NRF (2014R1A1A3049498) and the Bio & Medical Technology Development Program of the National Research funded by the Ministry of Science, ICT & Future Planning (2015M3A9B6074045 and 2015M3A9B6073827).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

Supplementary materials

Figure S1 Stability of chrysin-NPs.
Notes: Chrysin-NPs were stored at 4°C and 37°C for 12 h. Encapsulating percentage of chrysin-NPs was detected.
Abbreviation: NPs, nanoparticles.

Figure S2 No toxicity of NPs.
Notes: A549 cells (100 cells/well) were seeded in 6-well plate. After 24 h, NPs were added into media of A549 cells for 12 days. In clonogenic assay, colonies were counted and survival fraction was calculated.
Abbreviation: NPs, nanoparticles.